News

Over the last few months, as the world has grappled with the COVID-19 pandemic, the European Lead Factory has been looking for ways to contribute collective efforts and assets to help deal with the crisis. As part of this focus, we have decided to prioritise COVID-19 related proposals through a fast-track procedure. We're proud to announce that the first proposal to tackle the SARS-CoV-2 infection has now been selected. The screening program aims to identify small-molecule inhibitors of viral entry into host cells.

Metabomed, an Israeli biotech company that has been successful in progressing results through the European Lead Factory (ELF), has discovered a series of potent and selective inhibitors of ACSS2 (the AcetylCoA Short chain Synthase 2 enzyme) for the treatment of cancers dependent on acetate metabolism.

Professor dr. Huib Ovaa, ELF Academic Chemistry Partner and Public Programme Owner passed away on the 19^th of May 2020.

In this, the first in a series of articles in which we introduce various members of the European Lead Factory (ELF) Consortium, we’re pleased to feature an interview with Patricia Kramer-Verhulst. Patricia is a member of the ELF Programme Office – a team of ELF project members at Lygature. We asked Patricia to explain her role and what it is that interests her most about the project.